Literature DB >> 18082125

Identification of ryanodine receptor 1 single-nucleotide polymorphisms by high-resolution melting using the LightCycler 480 System.

Hilbert Grievink1, Kathryn M Stowell.   

Abstract

High-resolution melting (HRM) allows single-nucleotide polymorphism (SNP) detection/typing using inexpensive generic heteroduplex-detecting double-stranded DNA (dsDNA) binding dyes. Until recently HRM has been a post-PCR process. With the LightCycler 480 System, however, the entire mutation screening process, including post-PCR analysis, can be performed using a single instrument. HRM assays were developed to allow screening of the ryanodine receptor gene (RYR1) for potential mutations causing malignant hyperthermia (MH) and/or central core disease (CCD) using the LightCycler 480 System. The assays were validated using engineered plasmids and/or genomic DNA samples that are either homozygous wild type or heterozygous for one of three SNPs that lead to the RyR1 amino acid substitutions T4826I, H4833Y, and/or R4861H. The HRM analyses were conducted using two different heteroduplex-detecting dsDNA binding dyes: LightCycler 480 HRM dye and LCGreen Plus. Heterozygous samples for each of the HRM assays were readily distinguished from homozygous samples with both dyes. By using engineered plasmids, it was shown that even homozygous sequence variations can be identified by using either small amplicons or the addition of exogenous DNA after PCR. Thus, the LightCycler 480 System provides a novel, integrated, real-time PCR/HRM platform that allows high throughput, inexpensive SNP detection, and genotyping based on high-resolution amplicon melting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082125     DOI: 10.1016/j.ab.2007.11.019

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

1.  High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene.

Authors:  Yuko Doi; Daisuke Sasaki; Chiharu Terada; Sayaka Mori; Kazuto Tsuruda; Emi Matsuo; Yasushi Miyazaki; Kazuhiro Nagai; Hiroo Hasegawa; Katsunori Yanagihara; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2009-05-23       Impact factor: 2.490

Review 2.  High resolution melting applications for clinical laboratory medicine.

Authors:  Maria Erali; Karl V Voelkerding; Carl T Wittwer
Journal:  Exp Mol Pathol       Date:  2008-04-13       Impact factor: 3.362

3.  Association of ACE polymorphism and diabetic nephropathy susceptibility.

Authors:  Hongbo Ma; Che Yu; Rong Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping.

Authors:  E Pindurová; A Zourková; J Zrůstová; J Juřica; A Pavelka
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

5.  Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia.

Authors:  Hilbert Grievink; Kathryn M Stowell
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

6.  Functional analysis of RYR1 variants linked to malignant hyperthermia.

Authors:  Jeremy Stephens; Anja H Schiemann; Cornelia Roesl; Dorota Miller; Sean Massey; Neil Pollock; Terasa Bulger; Kathryn Stowell
Journal:  Temperature (Austin)       Date:  2016-02-26

7.  Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.

Authors:  Remai Parker; Anja H Schiemann; Elaine Langton; Terasa Bulger; Neil Pollock; Andrew Bjorksten; Robyn Gillies; David Hutchinson; Richard Roxburgh; Kathryn M Stowell
Journal:  J Neuromuscul Dis       Date:  2017

8.  Rapid screening for mutations associated with malignant hyperthermia using high-resolution melting curve analysis.

Authors:  I-Min Su; Po-Kai Wang; Chun-Yu Chen; Hsien-Tse Huang; Yuan-Ji Day
Journal:  Tzu Chi Med J       Date:  2021-04-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.